The Chief Executive of the ABPI and seven leaders from UK and European pharmaceutical and life science industry bodies, have written a joint letter to both the UK and EU Brexit negotiation teams. The letter underlines the importance of securing ongoing cooperation between the UK and EU on medicines.
It states that “Securing agreement [on ongoing cooperation between the UK and EU on medicines] is the best way of ensuring that patients across Europe and the UK are able to continue to access safe and effective medicines and to ensure that there is no adverse impact on public health.” This correspondence follows a recent letter published in the Financial Times by Jeremy Hunt, Secretary of State for Health, and Greg Clark, Secretary of State for Business, which outlined the UK Government’s plans for the regulation of medicines post-Brexit.
The absence of medical devices from the joint correspondence was subsequently noted in a letter to the Editor from Alan G Fraser, Emeritus Professor of Cardiology, Cardiff University. He stated that it was “odd to note, however, that they make no mention of medical devices — although the medical technology sector is just as important. Two new European laws were published on May 5, with the British Labour MEP Glenis Willmott serving as rapporteur while they went through their final stages of approval by the European Parliament… Expert regulators are in short supply and continued EU collaboration for medical device approvals is essential if these new standards are to be implemented.”
To read the letter from the pharmaceutical industry, please click here.